Centpropazine is a phenothiazine derivative with antipsychotic and antiemetic properties. It is a potent antagonist of dopamine and serotonin receptors. Centpropazine is synthesized by reacting chlorpromazine with propionic anhydride in the presence of a base. It is primarily studied for its potential therapeutic effects in schizophrenia, anxiety, and nausea. Research on centpropazine has investigated its efficacy, pharmacokinetics, and adverse effects. The compound exhibits a unique pharmacological profile, suggesting its potential utility in various clinical settings.'
| ID Source | ID |
|---|---|
| PubMed CID | 118176 |
| CHEMBL ID | 4303166 |
| SCHEMBL ID | 19852033 |
| MeSH ID | M0129444 |
| Synonym |
|---|
| centpropazine |
| AH-262/32491028 |
| 1-{4-[2-hydroxy-3-(4-phenyl-1-piperazinyl)propoxy]phenyl}-1-propanone |
| 1-(4-(2-hydroxy-3-(4-phenyl-1-piperazinyl)propoxy)phenyl)-1-propanone |
| centropazine |
| 1-propanone, 1-(4-(2-hydroxy-3-(4-phenyl-1-piperazinyl)propoxy)phenyl)- |
| 4'-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy)propiophenone |
| 3-(4-phenylpiperazinyl)-1-(4-propionylphenoxy)propan-2-ol |
| brn 0578135 |
| 1-(p-propionylphenoxy)-3-(4-phenylpiperazinyl)-2-propanol |
| propiophenone, 4'-(2-hydroxy-3-(4-phenylpiperazinyl)propoxy)- |
| OPREA1_270435 |
| 1-{4-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]phenyl}propan-1-one |
| AKOS002230306 |
| AKOS016302465 |
| 91315-34-3 |
| 1-[4-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]phenyl]propan-1-one |
| 34675-77-9 |
| STL232060 |
| r5ypg9la47 , |
| unii-r5ypg9la47 |
| F1757-0114 |
| 1-(4-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy)phenyl)propan-1-one |
| SCHEMBL19852033 |
| Z31370920 |
| VU0494485-1 |
| sr-01000206271 |
| SR-01000206271-1 |
| DTXSID00919825 |
| CHEMBL4303166 |
| CS-0021327 |
| EN300-6492994 |
Centpropazine is a new anti-depressant compound developed by Central Drug Research Institute, Lucknow (India)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Centpropazine is a new anti-depressant compound developed by Central Drug Research Institute, Lucknow (India). " | ( Development and validation of a new high-performance liquid chromatographic assay of centpropazine, a new antidepressant compound, in serum. Atul, BV; Gupta, RC; Paliwal, JK, 1999) | 1.97 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " CNPZ was characterized by a short elimination half-life (39." | ( Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats. Bhattaram, VA; Gupta, RC; Paliwal, JK, 2004) | 0.56 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The drug was found to be well absorbed from solution in in-situ studies." | ( Evaluation of absorbability of centpropazine in rats: in-situ and in-vivo appraoches. Atul, BV; Gupta, RC; Paliwal, JK, 2001) | 0.6 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||